<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8525C80A-080A-4EC7-90F8-ED6BB8560C64"><gtr:id>8525C80A-080A-4EC7-90F8-ED6BB8560C64</gtr:id><gtr:name>Animal Health and Veterinary Laboratories Agency (AHVLA)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/19A2A787-2FDB-4397-9885-403B7C582232"><gtr:id>19A2A787-2FDB-4397-9885-403B7C582232</gtr:id><gtr:name>Leiden University Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BB2319AB-8EEB-445A-8BB6-43D47D979CA9"><gtr:id>BB2319AB-8EEB-445A-8BB6-43D47D979CA9</gtr:id><gtr:name>Biomedical Primate Research Centre</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Unknown</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8525C80A-080A-4EC7-90F8-ED6BB8560C64"><gtr:id>8525C80A-080A-4EC7-90F8-ED6BB8560C64</gtr:id><gtr:name>Animal Health and Veterinary Laboratories Agency (AHVLA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/19A2A787-2FDB-4397-9885-403B7C582232"><gtr:id>19A2A787-2FDB-4397-9885-403B7C582232</gtr:id><gtr:name>Leiden University Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BB2319AB-8EEB-445A-8BB6-43D47D979CA9"><gtr:id>BB2319AB-8EEB-445A-8BB6-43D47D979CA9</gtr:id><gtr:name>Biomedical Primate Research Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ED099116-52CF-41E1-9F99-2ED0F3056923"><gtr:id>ED099116-52CF-41E1-9F99-2ED0F3056923</gtr:id><gtr:firstName>Elma</gtr:firstName><gtr:otherNames>Zaven</gtr:otherNames><gtr:surname>Tchilian</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B26F84B8-BD99-458F-87FD-67E85D1959E8"><gtr:id>B26F84B8-BD99-458F-87FD-67E85D1959E8</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Beverley</gtr:surname><gtr:orcidId>0000-0003-0481-2180</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/17719B3D-8D27-40E3-967A-65E55AE07A99"><gtr:id>17719B3D-8D27-40E3-967A-65E55AE07A99</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:surname>Hill</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701235"><gtr:id>28C3EEA9-1946-4B68-B8B8-70AC559A71B5</gtr:id><gtr:title>Correlates of protection against Mycobacterium tuberculosis infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701235</gtr:grantReference><gtr:abstractText>Tuberculosis is an increasing health problem because HIV increases individuals? susceptibility to the disease. Furthermore the bacteria are now often resistant to antibiotics, making treatment difficult. An improved vaccine would therefore be a major contribution to world health. Because Bacille Calmette-Guerin (BCG) the current vaccine, provides partial protection it is likely that any new vaccine will be used to boost the protection afforded by BCG. Several candidate booster vaccines are currently entering clinical trials to test their safety and ability to boost the immune response to tuberculosis. However, proving that a booster increases protection will require a very large, expensive and long clinical trial. A test that could indicate which vaccine candidates can boost protection, would allow a rational selection from among the available candidates and save a great deal of time, money and effort.
In our project we will study the lymphocytes from mice given BCG and then booster vaccines that are already known to increase protection or have no effect. This will allow us to compare the properties of protective and non-protective lymphocytes and identify a ?signature? of protection. We shall then use this in cows immunised against bovine tuberculosis, a disease that is very similar to human tuberculosis, to predict whether different booster immunisations are protective. Finally we shall study human volunteers given a candidate booster vaccine and predict whether this is a good candidate to go on to efficacy trials.</gtr:abstractText><gtr:technicalSummary>A number of vaccine candidates aimed at boosting protective immunity to M. tuberculosis (Mtb) above the level afforded by BCG, have entered or are close to, early phase clinical trials. Thus a test that would allow identification of effective booster vaccines without the need for efficacy trials would be extremely valuable. We have established an aerosol challenge mouse model in which BCG priming and intra-nasal boosting with a recombinant adenovirus expressing Mtb antigen 85A (Ad85A), induces strong protection against Mtb. We will study in detail the properties of T lymphocytes that are present in the lungs after this immunisation regime. Our hypothesis is that these cells are responsible for increased protection, are part of an endothoracic recirculating pool of memory and effector T cells and exhibit a distinct lung homing and functional signature, which will provide a correlate of increased protection. We will use multi-colour flow cytometry to analyse in detail the phenotype of lung resident 85A-specific T cells, identify their functional properties and perform gene expression analysis using microarrays. These properties will be compared to 85A-specific cells in the spleen induced by intra-nasal Ad85A or splenic 85A-specific cells induced by non-protective immunisation regimes, to identify a signature for lung homing protective cells. We shall then show that the protective signature can be detected in the blood following protective but not non-protective immunisation in mice. We shall go on to examine pre-challenge blood samples from cows immunised with BCG or prime boost regimes that provide increased protection over BCG alone. Finally we shall examine blood samples from human volunteers immunised with BCG followed by modified vaccinia Ankara containing antigen 85A. This project will identify a correlate of increased protection above that afforded by BCG alone in mice and show whether this can be used to provide predictive information in cows and humans.</gtr:technicalSummary><gtr:fund><gtr:end>2011-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>856744</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Animal Health And Veterinary Laboratories Agency (AHVLA)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Tuberculosis Research Unit</gtr:department><gtr:description>Simultaneous immunisation in bovines</gtr:description><gtr:id>9327DDE1-9AAF-42E0-9F45-438F7E62301F</gtr:id><gtr:impact>One joint publication</gtr:impact><gtr:outcomeId>goEQZ8EhucR-1</gtr:outcomeId><gtr:partnerContribution>Performance of a simultaneous immunisation experiment in cows to test the immunisation strategy.</gtr:partnerContribution><gtr:piContribution>Development of the simultaneous immunisation strategy for vaccination against tuberculosis.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Human pulmonary immune responses</gtr:description><gtr:id>4DDEB4C2-6E42-4E6A-BFD1-74F32AECB616</gtr:id><gtr:impact>We have obtained a joint MRC grant with this collaborator reference G1100085.</gtr:impact><gtr:outcomeId>GKDKneEazwc-1</gtr:outcomeId><gtr:partnerContribution>The collaboration aims to define protective pulmonary immune responses to M. tuberculosis in man. It has resulted in a successful joint grant application to the MRC.</gtr:partnerContribution><gtr:piContribution>We have developed the simultaneous immunisation procedure for tuberculosis which is the subject of the collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leiden University Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Department of Infectious Diseases</gtr:department><gtr:description>Antigens for simultaneous immunisation</gtr:description><gtr:id>E33BF88A-25E5-44B6-B4FD-680B90351996</gtr:id><gtr:impact>Two joint publications.</gtr:impact><gtr:outcomeId>EsztD5BYkir-1</gtr:outcomeId><gtr:partnerContribution>Supply of recombinant antigens for development of the novel simultaneous immunisation procedure against tuberculosis.</gtr:partnerContribution><gtr:piContribution>Performance of tuberculosis challenge experiments in mice using antigens supplied by the collaborator.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Animal Health And Veterinary Laboratories Agency (AHVLA)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Tuberculosis Research Unit</gtr:department><gtr:description>Further development of simultaneous immunisation</gtr:description><gtr:id>F2B585CC-444C-452A-9265-07B5B051B90A</gtr:id><gtr:impact>PMID: 21628524</gtr:impact><gtr:outcomeId>VTXWV4jvwWB-1</gtr:outcomeId><gtr:partnerContribution>Supply of recombinant antigens and testing of simultaneous immunisation strategy in cattle.</gtr:partnerContribution><gtr:piContribution>Development of the simultaneous immunisation strategy for tuberculosis. Testing of recombinant antigens by infectious TB chellenge in mice.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Max von Pettenkofer-Institute of Virology</gtr:department><gtr:description>Development of MCMV as a vaccine vector for tuberculosis</gtr:description><gtr:id>3526D356-CB87-4729-B5E1-B192D9E8108B</gtr:id><gtr:impact>One joint publication.</gtr:impact><gtr:outcomeId>kfKKVSxzjSx-1</gtr:outcomeId><gtr:partnerContribution>Partner constructs recombinant MCMVs containing M. tuberculosis antigens.</gtr:partnerContribution><gtr:piContribution>We immunise mice with recombinant MCMVs, analyse immune responses and perform infectious challenge experiments with M. tuberculosis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Biomedical Primate Research Centre</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Department of Parasitology</gtr:department><gtr:description>SIM in Primates</gtr:description><gtr:id>5A6CAB0B-161C-42DD-B95D-0161F0ADCA58</gtr:id><gtr:impact>Manuscript in preparation.</gtr:impact><gtr:outcomeId>jc1tD4DjSu2-1</gtr:outcomeId><gtr:partnerContribution>Collaborator carried out a SIM immunisation experiment in NHPs, which demonstrated the efficacy of mucosal immunisation with BCG..</gtr:partnerContribution><gtr:piContribution>Discovery of the SIM strategy for immunisation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Informing the public about tuberculosis</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F81D96C9-2CFA-465C-AE3C-B4DAB8456BCF</gtr:id><gtr:impact>A pop up shop in a shopping centre with games and information relating to tuberculosis in the UK.</gtr:impact><gtr:outcomeId>56d2d4258dd8e0.97565832</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture on Zoonoses</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2503DEBD-6BC5-46FF-A408-0E799F4AABB3</gtr:id><gtr:impact>A talk as part of the Big Biology Day at Hills Road College Cambridge.</gtr:impact><gtr:outcomeId>56d2d341d86fe6.20661911</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>992214</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1100085</gtr:fundingRef><gtr:id>16DB0093-CD4F-4FD8-A2BD-BD37C7BE1260</gtr:id><gtr:outcomeId>QTYsPZKa2PS0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>We have shown that CXCR6 is expressed on a subset lung lymphocytes, resident in the airways, after immunisation.The presence of CXCR6+ lymohocytes correlates with induction of protective immunity agains Mycobacterium tuberculosis.</gtr:description><gtr:grantRef>G0701235</gtr:grantRef><gtr:id>518F9DA3-6E96-4556-83FA-2D0E52F80187</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>M5XTvS8LcnT</gtr:outcomeId><gtr:patentId>WO2012025759</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>CXCR6 as a correlate of lung protective immunity after vacination</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>We have shown that simultaneous parenteral and pulmonary immunisation against Mycobacterium tuberculosis is more effective than immunisation by either route alone.</gtr:description><gtr:grantRef>G0701235</gtr:grantRef><gtr:id>EE7BED67-4A7C-4C6C-9626-893A3BEBC361</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>EpvoAKseydQ</gtr:outcomeId><gtr:patentId>WO2012052748</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Simultaneous immunisation</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>BCG Transmission Study Working Group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AF2D3100-8676-4A5F-BC92-A8357033E9D1</gtr:id><gtr:outcomeId>RQYB4Bg3cgH</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Vaccine policy advisory group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>955D9ED0-9D76-4BE7-9E70-FAC44EB2CB69</gtr:id><gtr:outcomeId>56d2d5b761c1b2.14541758</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>In pulmonary Mycobacterium tuberculosis (Mtb) infection, immune responses are delayed compared to other respiratory infections, so that antigen specific cells are not detected in the lungs earlier than day 14. Even after parenteral immunization with Bacille Calmette Guerin (BCG) or a subunit vaccine, the immune response after Mtb challenge is only slightly accelerated and the kinetics of pulmonary Mtb growth do not differ between na&amp;iuml;ve and immunised animals up to day 14. In contrast, intranasal immunization with Ad85A can inhibit early growth of Mtb because it establishes a lung antigen depot and maintains an activated lung-resident lymphocyte population.</gtr:description><gtr:id>29240DAA-68B5-41C6-BC9D-F1A8E4FA9CB6</gtr:id><gtr:impact>Two publications.</gtr:impact><gtr:outcomeId>EC97B5B1D3C</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Local immunity inhibiting early growth of Mycobacterium tuberculosis</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Microarray data has been obtained from CD8 T cells in the lungs of mice immunised intranasally with a recombinant adenovirus expressing Mycobacterium tuberculosis antigen 85A and compared to lung CD8 T cells from mice immunised with the same recombinant intradermally.</gtr:description><gtr:id>C9DB93A0-5BA6-44B7-80C4-6329245F7B4E</gtr:id><gtr:impact>Several genes are under investigation as correlates of effective local protective immunity to Mycobacterium tuberculosis. Two publications.</gtr:impact><gtr:outcomeId>74ECEF7ABA8</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Microarray data</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have constructed a human adenovirus type 5 recombinant virus expressing Mycobacterium tuberculosis antigen 85A.</gtr:description><gtr:id>DF0ECBC4-F807-4444-9B0C-376A1424FDE8</gtr:id><gtr:impact>We have used this virus to immunise mice intranasally and shown that it induces protective immunity inhibiting the early growth of Mycobacterium tubcerculosis in the lungs after aerosol challenge.</gtr:impact><gtr:outcomeId>F2DBD7B566E</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Ad85A</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E2B658C5-C60C-45BF-8617-9F12E88A09DC</gtr:id><gtr:title>Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc38a3c8d7daa55241aa596afb1e2901"><gtr:id>cc38a3c8d7daa55241aa596afb1e2901</gtr:id><gtr:otherNames>Forbes EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>7E8A24699E2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DF2BF88-141D-4D55-A352-3D9D6EF3CF86</gtr:id><gtr:title>Simultaneous immunization against tuberculosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ecfb469c69a353607a03c38a7d149e79"><gtr:id>ecfb469c69a353607a03c38a7d149e79</gtr:id><gtr:otherNames>Tchilian EZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>Tp6exBhQ87p</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>112A9890-EA68-448B-A0D6-17B7978F9F71</gtr:id><gtr:title>Immunization with different formulations of Mycobacterium tuberculosis antigen 85A induces immune responses with different specificity and protective efficacy.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddeb4b513a9a22a32e1292a5aaff3615"><gtr:id>ddeb4b513a9a22a32e1292a5aaff3615</gtr:id><gtr:otherNames>Tchilian E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_12944_24_23896422</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49CC12A0-DC33-4191-B7ED-151798D7D51C</gtr:id><gtr:title>Chemokine gene expression in lung CD8 T cells correlates with protective immunity in mice immunized intra-nasally with Adenovirus-85A.</gtr:title><gtr:parentPublicationTitle>BMC medical genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a38eea2cdba1a53a2340113ae7874224"><gtr:id>a38eea2cdba1a53a2340113ae7874224</gtr:id><gtr:otherNames>Lee LN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1755-8794</gtr:issn><gtr:outcomeId>AAPTkQTrrP9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55FA8E35-FB94-4E10-A0E3-1186AD00AF04</gtr:id><gtr:title>Environmental effects on protection against Mycobacterium tuberculosis after immunization with Ad85A.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2360a09cf36255b1c70e468e72ee2e71"><gtr:id>2360a09cf36255b1c70e468e72ee2e71</gtr:id><gtr:otherNames>Beverley P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_12944_24_23262169</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE3BF579-4325-4FC6-846B-352C536BA2F4</gtr:id><gtr:title>Harnessing local and systemic immunity for vaccines against tuberculosis.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f291f773af9424c3405959719846d950"><gtr:id>f291f773af9424c3405959719846d950</gtr:id><gtr:otherNames>Beverley PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>56d2dac2e553b6.02975461</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92600796-1CE7-4D9D-A182-30DCF10481D6</gtr:id><gtr:title>Lessons for tuberculosis vaccines from respiratory virus infection.</gtr:title><gtr:parentPublicationTitle>Expert review of vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f291f773af9424c3405959719846d950"><gtr:id>f291f773af9424c3405959719846d950</gtr:id><gtr:otherNames>Beverley PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1476-0584</gtr:issn><gtr:outcomeId>0E7FF0047CE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>320C94EA-240A-41AD-B11F-47D5BBA1CCD2</gtr:id><gtr:title>CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a38eea2cdba1a53a2340113ae7874224"><gtr:id>a38eea2cdba1a53a2340113ae7874224</gtr:id><gtr:otherNames>Lee LN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>UJmu2ZkkEqW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E41667B-3BD0-46D9-8F33-F4B656B0B0F5</gtr:id><gtr:title>Helicobacter hepaticus infection in BALB/c mice abolishes subunit-vaccine-induced protection against M. tuberculosis.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4712fa3ac01ed7fbc4f82a7afaf1db7"><gtr:id>c4712fa3ac01ed7fbc4f82a7afaf1db7</gtr:id><gtr:otherNames>Arnold IC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>56d2db024e0d92.76450109</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E627FFD8-40EA-4D74-9911-0DEBC1BA25EF</gtr:id><gtr:title>Protection Induced by Simultaneous Subcutaneous and Endobronchial Vaccination with BCG/BCG and BCG/Adenovirus Expressing Antigen 85A against Mycobacterium bovis in Cattle.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/857d04956b20a9e58bfd6d4bf6d15221"><gtr:id>857d04956b20a9e58bfd6d4bf6d15221</gtr:id><gtr:otherNames>Dean GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56d2db027c0126.42856774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F51CA262-5EEF-48FB-A672-5A5EF877D495</gtr:id><gtr:title>Nasal associated lymphoid tissue (NALT) contributes little to protection against aerosol challenge with Mycobacterium tuberculosis after immunisation with a recombinant adenoviral vaccine.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec01007f9b88dd2817ad8edd660d0a46"><gtr:id>ec01007f9b88dd2817ad8edd660d0a46</gtr:id><gtr:otherNames>Ronan EO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>gjZU8Vvuhfw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD8156FD-7158-4BD1-A1E4-108748273244</gtr:id><gtr:title>Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec01007f9b88dd2817ad8edd660d0a46"><gtr:id>ec01007f9b88dd2817ad8edd660d0a46</gtr:id><gtr:otherNames>Ronan EO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>78472A14864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88DE081B-4452-4410-A5E4-015C1256FB65</gtr:id><gtr:title>A novel murine cytomegalovirus vaccine vector protects against Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f291f773af9424c3405959719846d950"><gtr:id>f291f773af9424c3405959719846d950</gtr:id><gtr:otherNames>Beverley PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>56d2dac2b51391.84918623</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701235</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>